Respiratory superbugs
Pseudomonas aeruginosa is a type of bacteria that can infect people with long-term lung problems. If it isn’t quickly treated with the right antibiotics, the bacteria can form protective layers called biofilms. These biofilms make the infection very hard to get rid of.
Over 400 million at risk worldwide
People with COPD and bronchiectasis are especially vulnerable to respiratory superbugs.
Repeated hospital visits
Respiratory superbugs that are not treated with the right antibiotic can cause permanent lung damage, increasing healthcare costs.
Rapid testing at the point of care
Nanodecal offers the first test to identify bacteria in sputum within minutes. A reagent liquefies the sample, and a rapid test detects bacteria. These tests can be used anywhere in healthcare, making them ideal for guiding antibiotic treatments.
Enabling precision
Nanodecal’s rapid test identifies bacteria quickly, enabling personalized treatments that are faster and more effective.
Sample liquefaction for point of care detection
Sputum samples, which contain bacteria causing lung infections, is thick and nearly solid, making point-of-care analysis difficult. Nanodecal solves this problem with a reagent that liquefies sputum in just 1-2 minutes. Patent WO2021224529A1
At the point of care
Complete liquefaction with our reagent that does not require laboratory equipment.
Multiple applications
Preserves bacteria and biomarkers for detection with immunoassays. Keeps leukocytes intact for detection with flow cytometry.
A new antigen test for rapid lung diagnosis
Antibody-coated nanoparticles are contact-transferred, overcoming the limitations of lateral flow tests. They are produced using our proprietary method, protected under patent WO2021048087A1.
High sensitivity and specificity
Thanks to the simultaneous detection of multiple antigens of the same pathogen.
Our Team
We are putting together a multidisciplinary team to bring Nanodecal's tech from bench to market.
Roberto de la Rica
CEO | FounderI am committed to help Nanodecal grow so that our technology can help patients. I am thrilled by the idea of guiding therapeutic decisions using scientific evidence obtained on the spot.
Steven M. Russell
Quality & Regulatory Affairs ManagerI am dedicated to developing and maintaining the quality management system and to mananging regulatory affairs to support the growth of Nanodecal.
Stephanos Papaefstathiou
COOWith a strong foundation in public health, I am engaged in fostering teamwork and collaboration throughout Nanodecal's operations.
Isabel Pérez Guillén
CSOI am deeply passionate about clinical microbiology and hold a PhD in the field, which underscores my commitment to supporting Nanodecal's growth and enhancing patient care
Xavier Riba
CFOBusiness professor, specialist in finance and entrepreneurship with over 20 years of experience
Cristina Adrover
R&D Director| FounderI'm a passionate R&D specialist and company founder, devoted to advancing healthcare through developing cutting-edge biosensor technology.
Ana Losada
CTOI am a Biomedical Engineer supporting product design, development, and production at Nanodecal
Advisory Board
Marcio Borges
President of the Code Sepsis Foundation and Director of the Sepsis Area at FEPIMCTI
Borja García-Cosío
Coordinator of the National Strategy on COPD for the Balearic Islands
Antonio Oliver
Head of Clinical Microbiology at HUSE and world expert in Pseudomonas infections
Antonio Ornelas
Advisor for Life Sciences & Medical Technology for Venture Capital Co.
.png){kind=logo}
